Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2025)
Historic Operating Leases for Fulcrum Therapeutics (FULC) over the last 4 years, with Q3 2025 value amounting to $4.7 million.
- Fulcrum Therapeutics' Operating Leases fell 3349.02% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3349.02%. This contributed to the annual value of $6.4 million for FY2024, which is 2533.32% down from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Operating Leases is $4.7 million, which was down 3349.02% from $5.3 million recorded in Q2 2025.
- Fulcrum Therapeutics' Operating Leases' 5-year high stood at $12.8 million during Q1 2022, with a 5-year trough of $4.7 million in Q3 2025.
- Its 4-year average for Operating Leases is $8.7 million, with a median of $8.6 million in 2023.
- Its Operating Leases has fluctuated over the past 5 years, first tumbled by 2004.54% in 2024, then plummeted by 3349.02% in 2025.
- Quarter analysis of 4 years shows Fulcrum Therapeutics' Operating Leases stood at $10.8 million in 2022, then decreased by 20.26% to $8.6 million in 2023, then fell by 25.33% to $6.4 million in 2024, then dropped by 27.63% to $4.7 million in 2025.
- Its Operating Leases stands at $4.7 million for Q3 2025, versus $5.3 million for Q2 2025 and $5.9 million for Q1 2025.